文献速递贫血与红细胞疾病

药物治疗减轻严重母体红细胞同种免疫所致胎儿贫血

Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation.
PubMed 文献 · Br J Haematol · 2020-08-14

本综述聚焦于严重早发性胎儿贫血的HDFN人群,讨论在妊娠早期开始使用静脉免疫球蛋白(IVIg)和新型单克隆抗体(M281,nipocalimab)治疗,以减弱IgG抗体的胎盘通过及对胎儿的影响,从而可能改善需早期宫内输血的严重HDFN胎儿的存活。

要点

  • 宫内胎儿输血是严重胎儿贫血的首选治疗,但侵入性操作有流产和早产风险。
  • 在22周前因严重早发性胎儿贫血行宫内输血时,操作相关风险增加。
  • 综述讨论IVIg和新型单克隆抗体M281(nipocalimab)在孕早期末开始使用可能减弱IgG抗体的胎盘通过及胎儿效应。

核心结论

  • 在孕早期末开始IVIg或M281(nipocalimab)治疗可能减弱IgG抗体的胎盘通过及胎儿效应,从而可能改善需早期宫内输血的严重HDFN胎儿的存活,并可能对围产期管理产生更广泛影响。

研究设计与样本

  • 综述,聚焦于严重早发性胎儿贫血的HDFN人群。

主要发现

  • 宫内胎儿输血是严重胎儿贫血的首选治疗。
  • 侵入性胎儿治疗存在流产和早产风险。
  • 在22周前因严重早发性胎儿贫血行宫内输血时,操作相关风险增加。
  • IVIg和M281(nipocalimab)若在孕早期末开始使用,可能减弱IgG抗体的胎盘通过及胎儿效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of fetal mortality with potential neonatal and longer-term morbidity. HDFN is caused by maternal red cell alloimmunisation, with IgG antibodies crossing the placenta to destroy fetal erythroid cells expressing the involved antigen. Intrauterine fetal blood transfusion is the therapy of choice for severe fetal anaemia. Despite a strong evidence base and technical advances, invasive fetal therapy carries risk of miscarriage and preterm birth. Procedure-related risks are increased when invasive, in utero transfusion is instituted prior to 22 weeks to treat severe early-onset fetal anaemia. This review focuses upon this cohort of HDFN and discusses intravenous immunoglobin (IVIg) and novel monoclonal antibody (M281, nipocalimab) treatments which, if started at the end of the first trimester, may attenuate the transplacental passage and fetal effects of IgG antibodies. Such therapy has the ability to improve fetal survival in this severe presentation of HDFN when early in utero transfusion may be required and may have wider implications for the perinatal management in general.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Castleman JS, Moise KJ, Kilby MD, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2020. PMID: 32794242. doi:10.1111/bjh.17041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。